What is the main purpose of this filing?

This filing is a 10-Q Quarterly Report for Regeneron Pharmaceuticals, Inc., which provides an update on the company's financial performance and operational activities for the first quarter of the fiscal year 2000. It is a required filing with the U.S. Securities and Exchange Commission (SEC).

Can I find specific financial numbers like revenue or profit in the provided text?

No, the provided text is an EDGAR directory listing and does not contain the detailed financial statements, such as revenue, expenses, or net income, typically found in a full 10-Q report. To find these specific numbers, you would need to access the complete filing document.

What kind of information should investors look for in a full 10-Q filing from Regeneron?

Investors should look for details on the company's revenue streams, research and development expenses, progress on its drug pipeline, any clinical trial updates, regulatory approvals or setbacks, cash position, and overall profitability. The full 10-Q would also include management's discussion and analysis of financial condition and results of operations.

REGN 10-Q Quarterly Report Q1 FY2000 — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending March 30, 2000. This report provides a snapshot of the company's financial standing and operational activities during the first quarter of 2000. Investors should note that specific financial figures and operational details are not present in the provided filing text, which appears to be an EDGAR directory listing rather than the full 10-Q report. Therefore, a detailed financial analysis is not possible based solely on this excerpt. Investors would typically look to the full filing for revenue, expenses, net income, cash flow, and key developments in drug pipeline and regulatory status.

Key Highlights

1The filing is a 10-Q for Regeneron Pharmaceuticals, Inc. for the period ending March 30, 2000.
2The report was filed with the SEC on May 11, 2000.
3The provided text is a directory listing from the EDGAR database, not the complete financial report.
4Key financial and operational details are not available in this excerpt.
5Investors would normally expect to find information on revenue, expenses, net income, and cash flows within a 10-Q filing.

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q1 Ended Mar 31, 2000

Summary

Key Highlights

Frequently Asked Questions